Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 24;12(1):286.
doi: 10.1186/s13104-019-4321-1.

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada

Jonathan Heppner  1 , Leonard Tu Nguyen  2 , Maggie Guo  2   3 , Christopher Naugler  2   3   4 , Fariborz Rashid-Kolvear  5   6   7
Affiliations

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada

Jonathan Heppner et al. BMC Res Notes. .

Abstract

Objective: The incidence of the combined myeloproliferative neoplasms (MPNs) was determined for a major Canadian city. Retrospective cases of MPN diagnoses (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) between 2011 to 2015 were retrieved from the Southern Alberta Cancer Cytogenetics Laboratory's database at Alberta Public Laboratories.

Results: An incidence rate of 2.05 cases per 100,000 person-years (95% CI 1.73-2.41) was determined, giving an age-standardized Canadian incidence of 2.71 cases per 100,000 person years (95% CI 2.63-2.78). MPN diagnoses occurred at a wide age range of 8-93 (median 66) and an age-dependent increase in incidence. Incidence rates for the MPNs are first reported here for a Canadian population.

Keywords: Cancer epidemiology; Essential thrombocythemia; Hematological neoplasm; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Age and sex-categorized incidence rates of myeloproliferative neoplasms in the Calgary metropolitan area (2011–2015)
See this image and copyright information in PMC

References

    1. Swerdlow SHC, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4. Lyon: IARC Press; 2008.
    1. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97–105. doi: 10.1001/jamaoncol.2015.89. - DOI - PubMed
    1. Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581–587. doi: 10.1002/ajh.23690. - DOI - PubMed
    1. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol. 2015;141:2131–2138. doi: 10.1007/s00432-015-1983-5. - DOI - PMC - PubMed
    1. Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017;98:85–93. doi: 10.1111/ejh.12788. - DOI - PubMed

MeSH terms